Prosper Xtandi

01 Hatanaka-san Introduction 161202 Final
XTANDI, overactive bladder treatments Near term Turn innovative science into value for patients on the forefront of healthcare change PROSPER PIII study Ongoing Local Castration Anti-Androgens Chemotherapy Therapy*1 M0 BCR EMBARK PIII study M1 HSPC ARCHES PIII study*2 Ongoing ... Fetch Content

MEDIVATION INC (MDVN) Earnings Report: Q1 2016 Conference ...
XTANDI, our blockbuster prostate cancer drug partnered with Astellas If SPARTAN result positively, we have the option of unblinding PROSPER early if we so choose. If SPARTAN misses, we can wait to unblind to increase our chances of success. With respect to talazoparib this year ... Retrieve Document

Phase III Trials For Xtandi (MDV3100) - HealthAce
Phase III Trials for Xtandi (MDV3100) Sources: Company Reports; 5+ Brokerage Analyst Reports . (PROSPER study), the metastatic hormone-sensitive setting (TERRAIN and STRIVE studies), the neoadjuvant setting, and the frontline hormonal setting, ... Fetch This Document

Clinical Pdate CLINICAL UPDATE - Hematology & Oncology
Clinical pdate CLINICAL UPDATE Novel Approaches to Disease Management Biotech], enzalutamide [Xtandi, Astellas/Medivation]), chemotherapeutic agents (docetaxel, cabazitaxel [Jevtana, (PROSPER). https://clinicaltrials. ... Get Document

Pfizer Inc Conference Call To Provide Update On Oncology ...
And with that, we are pleased to share that the readout of Xtandi PROSPER trial in non-metastatic, castration-resistant prostate cancer has been accelerated by 2 years. Our team identified a protocol amendment that we anticipate will allow us to obtain top line results for the primary endpoint ... Retrieve Content

Goldman Sachs Healthcare Conference - S21.q4cdn.com
Goldman Sachs Healthcare Conference Mikael Dolsten M.D., Ph.D. June 14, 2017 . Xtandi non meta. PROSPER/EMBARK . Inflammation & Immunology. 6. AK1 Atopic DermatitisJ 7. JAK3 , TYK2/JAK1 Alopecia 8. eljanzX Psoriatic Arthritis & Ulcerative Colitis . ... Read More

ProstateCancerExpertPanelPositiveonXtandi Medivation
Xtandi expected to grow in the urology, thanks to STRIVE and TERRAIN ph3 studies PROSPER and SPARTAN to read out before making M0 utilization widespread (note that M0 isn't in our model). In terms of combo utilization, ... Get Content Here

Forskningsnyt - Clin.au.dk
PSA stigning > 2.0 ng/ml PROSPER Susanne: 52636 PSA fordobling < 10 mdr Forskningsnyt Opstart af Xtandi, Zytiga eller Taxotere Alle CRPC-ptt, som progredierer på PSA CRPC Edda: 52724 Opstart af Xtandi Alle pt der opstarter Xtandi-beh. Registrerings-studie ... Read More

Dean.mastrojohn@pfizer - Cmsastellas.ca
Previously the expected primary completion date for PROSPER was June 2019. “XTANDI is already a standard of care for men worldwide fighting metastatic castration-resistant prostate cancer, but we are continually looking to evaluate this medicine for men ... Access Content

Ongoing Prostate Cancer Trials For Xtandi (MDV3100)
Phase III; PROSPER (Non-Metastatic Patients) 2º: OS, Time to pain progression, 1st use of cytotoxic chemo, 1st use of new antineoplastic Xtandi will become a blockbuster drug as early line prostate cancer opportunities will drive peak global Xtandi sales to $6.8bn. ... Fetch Doc

XTANDI (enzalutamide) - Caremark
XTANDI (enzalutamide) RATIONALE FOR INCLUSION IN PA PROGRAM. Background. Xtandi is indicated for men with castration-resistant prostate cancer (prostate cancer that is ... Document Retrieval

Safety And Efficacy Study Of Enzalutamide In Patients With ...
Prostate Cancer (PROSPER) Purpose The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer. Xtandi Eligibility Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Male ... Retrieve Full Source

David Hung, M.D. - Files.shareholder.com
Completed, ongoing or planned clinical trials to support approval of our product candidates or expand the label for XTANDI PROSPER, mHSPC) •Phase 3 trial in Triple Negative Breast Cancer (TNBC) may start in 2H 2016 ... View This Document

Medivation Reports Fourth Quarter And Year -End 2013 ...
XTANDI is approved in more than 35 countries for the treatment of patients with mCRPC who have previously received Initiated the Phase 3 PROSPER trial in December 2013 evaluating the safety and efficacy of enzalutamide in ... Access Content

Strategic Plan 2015-2017 - Astellas Pharma
Strategic Plan 2015-2017 . I. Strategy Maximizing the Product Value Maximize XTANDI rapidly in the chemo-naive indication, [PROSPER study] M0 CRPC Non-metastatic CRPC . Placebo-controlled, n=1,500 : ... Get Content Here

Medivation (MDVN) Earnings Report: Q4 2015 Conference Call ...
XTANDI having been approved approximately two years later. We believe that an important near-term commercial opportunity for XTANDI in MCRPC is in early new treatment lines for patients who are primarily treated by urologists. ... Return Doc

Safety And Efficacy Study Of Enzalutamide In Patients With ...
Trial record 4 of 30 for: prosper Previous Study | Return to List | Next Study Xtandi Eligibility Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: ... Doc Retrieval

Medivation, Inc. - Zacks Small Cap Institutional Research
San Francisco based Medivation, Inc. is a biopharmaceutical company that focuses on the development (PROSPER) in patients with non-metastatic castration- Xtandi Soars Feb 25 Medivation Inc. (MDVN) ... Retrieve Doc

Tratamiento CPRC: Abiraterona Vs - Forodebateoncologia.net
Tratamiento CPRC: Abiraterona vs Enzalutamida. ¿Porqué recomendaría una de estas EPAR Xtandi 2014 Ficha Técnica Xtandi PROSPER Enzalutamide post abiraterone ... Read Document